Pharmacovigilance is undergoing a fundamental shift as artificial intelligence transforms how pharmaceutical companies detect, monitor, and respond to drug safety signals.
Writing for Pharmaceutical Commerce, Updesh Dosanjh of IQVIA argues that AI-powered pharmacovigilance is fast becoming a strategic commercial imperative, not merely a regulatory obligation.
Dosanjh, who serves as IQVIA’s practice leader for pharmacovigilance technology solutions, says the volume and complexity of safety data have simply outpaced traditional monitoring capabilities across the industry.
The pharmaceutical and biopharmaceutical sectors have long maintained what Dosanjh describes as “an unwavering dedication to patient safety,” embedded at every stage of drug development and manufacturing.
Effective monitoring and resolution of safety concerns now address not only regulatory compliance but also the commercial performance of drugs across their entire lifecycle.
Dosanjh warns that inaccurate or inconsistent reporting, overlooked signals, or delays “can result in costly setbacks that ripple across development timelines to delay market access and erode long-term trust.”
Executives responsible for commercialisation are urged to keep safety firmly at the centre of strategic planning, treating it as a driver of cost efficiency and competitive advantage rather than a back-office function.
AI tools are seen as central to meeting this challenge, enhancing pharmacovigilance by reducing costs, improving decision-making, and enabling more efficient analysis of increasingly diverse safety datasets.
Regulatory bodies are also actively promoting AI adoption to address safety data challenges, according to the article, urging organisations to invest in systems that ensure both compliance and long-term commercial viability.
Successful integration of AI into safety operations, Dosanjh notes, requires cross-functional collaboration, strong data governance, and a cultural shift that repositions pharmacovigilance as a core element of commercial strategy.
The argument concludes that those who harness AI to transform safety data into actionable intelligence “will be best positioned to safeguard patients while remaining competitive in a crowded market.”
Dosanjh frames intelligent pharmacovigilance as something that is becoming “not just a compliance necessity but a commercial imperative” across the full drug development lifecycle.
For an industry where, as the article puts it, “trust and time are worth their weight in gold,” the stakes of getting drug safety monitoring right have rarely been higher.